MCL1 is a member of a family of genes that control the viability of cells. MCL1 is abundantly expressed in multiple myeloma and contributes to the prolonged survival of these cells. This work aims to convert MCL1 to alternate forms to kill multiple myeloma cells. We will first optimize MCL1 conversion to alternate forms, and will monitor the effects on multiple myeloma cell death and chemotherapeutic responsiveness. We will also develop approaches for converting MCL1 to alternate forms for therapeutic application for multiple myeloma. Conversion of pro-survival MCL1 to pro-death forms represents a novel approach for therapy of this disease.